Subject Index

Actin 166 Adhesions 14 Angiogenesis 159 Anti-angiogenesis 159 Anticoagulants 30 Anticoagulation 4 Anti-factor Ha activity 74 Xa 180 - activity 74. 129 Antithrombin 14, 129, 146, 180 Arteriosclerosis 166 Artery 166 Atherosclerosis 50 Atherosclerotic heart disease 102 Blood vessels 166 C5 epimerase 146 Clinical trials 205 Coagulation 14 Coronary artery disease 102 Cytoskeleton 166 N-Deacetylation 146 Deep vein thrombosis 4 - , prophylaxis 74 venous thrombosis 220 Duplex sonography 205 Endothelial cell 50 Endothelium 14, 30, 129 Extracellular matrix 159 Extrinsic pathway inhibitor 30 Feedback thrombin generation 81 Fibrinolysis 14, 50 Fibroblast growth factor 159 Glucosamine 146 Glucuronic acid 146 Glycosaminoglycans 30, 166 Growth 159 Haemostasis 14 Hemorrhage 220 Heparan sulfate 146 Heparin 4, 81, 94, 98, 113, 122, 132, 146, 180, 205 - activity 62 - , alternative administration routes 154 antithrombotic therapy 129 binding 62 conformation 62

Low molecular-weight heparin(s) Unfractionated heparin 74, 4, 74, 81, 94, 159, 205, 220 Unstable angina 102, 113

fractions 74 fragments 74 oral administration 154 structure 62 Heparin-binding proteins 30 Hypercoagulability 50 Iduronic acid 146 Injured vessel wall 30 Injury 166 Ion-paired heparin 154 Matrix 166 Monocytes 98 Myocardial infarction 122 - , secondary prevention 132 ischemia 113 Pentasaccharide 81 Pharmacokinetics 94 Phlebography 205 Platelet factor 4 81 Platelets 14 Postthrombotic syndrome 220 Prostacyclin 30 Protease inhibitors 30 Protein S 14 - pathway 30 S 14 Prothrombin conversion 81 Pulmonary embolism 193, 220 Repair 166 Smooth muscle cells 159 Sulfotransferase 146
Vascular anticoagulant 30
Thrombin 81 Thromboembolism 193 Thrombolysis 122 Thrombomodulin 30 Thrombosis 205 -, mechanism 50 -, pathogenesis 50 Tissue factor 50, 98